- Home
- CRSP vs SGHC Comparison
CRSP vs SGHC Comparison
Compare CRSP & SGHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- SGHC
- Stock Information
- Founded
- CRSP 2013
- SGHC 2020
- Country
- CRSP Switzerland
- SGHC Guernsey
- Employees
- CRSP N/A
- SGHC N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- SGHC Services-Misc. Amusement & Recreation
- Sector
- CRSP Health Care
- SGHC Consumer Discretionary
- Exchange
- CRSP Nasdaq
- SGHC Nasdaq
- Market Cap
- CRSP 3.4B
- SGHC 3.6B
- IPO Year
- CRSP 2016
- SGHC N/A
- Fundamental
- Price
- CRSP $37.77
- SGHC $7.64
- Analyst Decision
- CRSP Buy
- SGHC Strong Buy
- Analyst Count
- CRSP 19
- SGHC 5
- Target Price
- CRSP $74.35
- SGHC $10.80
- AVG Volume (30 Days)
- CRSP 2.4M
- SGHC 892.0K
- Earning Date
- CRSP 05-07-2025
- SGHC 05-08-2025
- Dividend Yield
- CRSP N/A
- SGHC 3.80%
- EPS Growth
- CRSP N/A
- SGHC N/A
- EPS
- CRSP N/A
- SGHC 0.23
- Revenue
- CRSP $37,314,000.00
- SGHC $1,756,759,499.00
- Revenue This Year
- CRSP $51.35
- SGHC $15.33
- Revenue Next Year
- CRSP $282.16
- SGHC $9.20
- P/E Ratio
- CRSP N/A
- SGHC $32.87
- Revenue Growth
- CRSP N/A
- SGHC 18.16
- 52 Week Low
- CRSP $30.04
- SGHC $2.90
- 52 Week High
- CRSP $67.88
- SGHC $8.51
- Technical
- Relative Strength Index (RSI)
- CRSP 49.46
- SGHC 63.16
- Support Level
- CRSP $36.74
- SGHC $6.34
- Resistance Level
- CRSP $40.13
- SGHC $7.17
- Average True Range (ATR)
- CRSP 2.67
- SGHC 0.37
- MACD
- CRSP 0.72
- SGHC 0.15
- Stochastic Oscillator
- CRSP 76.62
- SGHC 98.32
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About SGHC Super Group (SGHC) Limited
Super Group (SGHC) Ltd is a holding company that operates global online sports betting and gaming businesses. The company has two reportable segments, namely Betway and Spin. The majority of the company's revenue comes from the Betway segment, which is a single-brand online sportsbook business with a global reach. Betway has formed strategic partnerships with teams and leagues across the world and recovers sponsorship marketing spend through brand license agreements. The Betway segment generates the majority of the company's revenue.